First heart patients implanted with next-generation mechanical heart pumpJune 03, 2009hree patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first in the United States to be implanted with a next-generation artificial heart pump called the DuraHeart™ Left-Ventricular Assist System. The surgeries took place earlier this year. NewYork-Presbyterian/Columbia is one of only three centers in the U.S. currently enrolling patients in a clinical trial studying the device. The DuraHeart is designed to sustain patients with severe left-ventricular heart failure while they wait for a heart transplant. Without intervention, they are at risk of death. The surgeries were led by Dr. Yoshifumi Naka, director of cardiac transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center and associate professor of surgery at Columbia University College of Physicians and Surgeons. He elected to implant the device without stopping the heart and putting the patient on a heart-lung machine. This "off pump" approach reduces risk for bleeding and stroke associated with putting a patient on bypass. "In this clinical trial, we hope to show that this device can help patients retain a healthy and meaningful quality of life while awaiting a heart transplant," says Dr. Naka, one of three national co-principal investigators of the DuraHeart trial. "Eventually, the DuraHeart may also prove to be a long-term solution, even for those ineligible for transplantation." There are fewer than 2,500 hearts transplanted each year in the United States, while 500,000 to 800,000 patients have advanced heart failure; many do not qualify for transplantation due to other health issues. The average wait for a transplant is nine months due to a shortage of donor organs. In patients with advanced heart failure, their heart isn't strong enough to pump sufficient blood for normal activities, leaving them greatly fatigued and frequently bedridden with difficulty breathing; heart failure is the number one reason for hospitalization. Mechanical heart pumps like the DuraHeart are designed to help the heart pump blood from the left ventricle to the aorta, increasing flow throughout the body. Previous research has shown the approach can help alleviate symptoms and improve survival. The first left-ventricular assist device, or LVAD, became available in the mid-1980s. Since then, the technology has improved, becoming more compact and with fewer moving parts -- including through clinical research at NewYork-Presbyterian/Columbia leading to the FDA approval of Thoratec's HeartMate® and HeartMate® II. The DuraHeart is considered a third-generation device, with unique features -- including a paddlewheel-like component called an impeller that is suspended by an electromagnet -- eliminating any bearings or contact points and allowing it to work at slower speeds, potentially reducing device wear and risk for blood cell breakage. New York- Presbyterian Hospital/Columbia University Medical Center |
|||||||||||||||||||||
| Related Heart Pump Current Events and Heart Pump News Articles Texas Children's discharges first pediatric patient with implanted mechanical heart device Texas Children's Hospital is the nation's first pediatric hospital to discharge a child while on an intracorporeal ventricular assist device (VAD), a feat previously accomplished only at adult institutions. UT Southwestern patient first in North Texas to receive newest-generation heart failure device UT Southwestern Medical Center patient Michael LeBlanc, 40, is the first in North Texas to receive the newest generation of a mechanical device designed to improve heart function. It will be his lifeline while he awaits a heart transplant. 'Beating' heart machine expedites research and development of new surgical tools, techniques A new machine developed at North Carolina State University makes an animal heart pump much like a live heart after it has been removed from the animal's body, allowing researchers to expedite the development of new tools and techniques for heart surgery. Exercise is safe, improves quality of life in patients with chronic heart failure Regular exercise is safe for heart failure patients and may slightly lower their risk of death or hospitalization, according to results from the largest and most comprehensive clinical trial to examine the effects of exercise in chronic heart failure patients. Artificial pump effectively backs up failing hearts Patients with severe heart failure can be bridged to eventual transplant by a new, smaller and lighter implantable heart pump, according to a just-completed study of the device. Many African-Americans have a gene that prolongs life after heart failure About 40 percent of African-Americans have a genetic variant that can protect them after heart failure and prolong their lives, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions. National study will look at German-made heart pump for children needing heart transplants Texas Children's Hospital has been named the national lead center for a 12-hospital, 36-month clinical trial of the German-manufactured pediatric heart pump called Berlin Heart EXCOR® Pediatric Ventricular Assist Device (VAD). Smaller heart pump bridges time to transplant for more women A small, implantable device that helps the heart pump blood works equally well for men and women but may benefit twice as many women awaiting transplants. Experts debate role of stenting, bypass surgery in left main coronary artery disease Coronary artery bypass surgery has been the preferred treatment for patients with a blockage in the left main coronary artery, the conduit that supplies blood to about two-thirds of the heart. New therapies may help some end-stage heart failure patients avoid transplant Implanted pumps improved heart function enough in a small percentage of patients awaiting a heart transplant that they were able to leave the hospital without a pump and without a new heart. More Heart Pump Current Events and Heart Pump News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||